PMC:7696151 / 23692-23949 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"702","span":{"begin":4,"end":12},"obj":"Species"},{"id":"712","span":{"begin":148,"end":168},"obj":"Chemical"},{"id":"713","span":{"begin":199,"end":208},"obj":"Chemical"},{"id":"714","span":{"begin":244,"end":247},"obj":"Chemical"}],"attributes":[{"id":"A702","pred":"tao:has_database_id","subj":"702","obj":"Tax:9606"},{"id":"A713","pred":"tao:has_database_id","subj":"713","obj":"MESH:D012254"},{"id":"A714","pred":"tao:has_database_id","subj":"714","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"All patients were randomized and divided into two groups; the control group treated with standard-of-care (SOC) consisted of 160 µg of subcutaneous pegylated interferon and 1000–12000 mg/day of oral ribavirin, and the group treated with 200 mg HCQ plus SOC."}

{"project":"LitCovid-sentences","denotations":[{"id":"T166","span":{"begin":0,"end":257},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"All patients were randomized and divided into two groups; the control group treated with standard-of-care (SOC) consisted of 160 µg of subcutaneous pegylated interferon and 1000–12000 mg/day of oral ribavirin, and the group treated with 200 mg HCQ plus SOC."}